| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 1
Bioactivity of hexokinase II inhibitor ikarugamycin and relation with tissue factor in breast cancer cell lines
1 Istanbul Medipol University, Faculty of Medicine, Department of Biochemistry, Istanbul, Türkiye
DOI :
10.23893/1307-2080.APS6312